FLI
BCLI

Family Legacy Inc’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Family Legacy Inc’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-13
Closed -$1K – 115
2018
Q4 		$1K Hold
13
– – ﹤0.01% 163
2018
Q3 		$1K Hold
13
– – ﹤0.01% 167
2018
Q2 		$1K Buy
+13
New +$765 ﹤0.01% 167

Other funds holding BCLI

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CIBC Private Wealth Group
CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
PVH
Psagot Value Holdings Tel Aviv, Israel $11M AUM 32.09% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Family Legacy Inc's BCLI Position: Q1 2019 in Review

Family Legacy Inc sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q1 2019, closing a stake of 13 shares — an estimated $1K sold.

Family Legacy Inc first reported a position in BCLI in Q2 2018 and held it in 3 quarters. The position peaked at $1K in Q4 2018. 38 funds tracked by Wall St. Rank hold BCLI as of Q1 2019.

  • Family Legacy Inc reported no remaining BRAINSTORM CELL THERAPUTC position as of Q1 2019 after selling out during the quarter.
  • Family Legacy Inc sold 13 BRAINSTORM CELL THERAPUTC shares in Q1 2019, an estimated $1K.
  • Family Legacy Inc first reported a position in BRAINSTORM CELL THERAPUTC in Q2 2018 and held it in 3 quarters.
  • Family Legacy Inc's BRAINSTORM CELL THERAPUTC position peaked at $1K in Q4 2018.
  • 38 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q1 2019.

Based on Family Legacy Inc's 13F filing for Q1 2019, filed 6 May 2019.